Clinical trial
TG4040 in Patients With Chronic HCV
NCT00449124 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00449124 |
|---|---|
| Title | TG4040 in Patients With Chronic HCV |
| Official title | A Phase I, Randomized, Double-Blind, Dose-Ranging, Crossover Trial of HCV Vaccine (TG4040) in Patients With Chronic Hepatitis C to be Conducted in Two Parts |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Biological, Drug |
| Interventions | Placebo, TG4040 |
| Enrollment | 0 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Mar 19, 2007 |
| Last update posted | Jan 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: